REG - Hemogenyx Pharma Plc - Issue of Equity

Hemogenyx PharmaceuticalsAnnouncement

10/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260210:nRSJ3171Sa&default-theme=true

RNS Number : 3171S  Hemogenyx Pharmaceuticals PLC  10 February 2026

10 February 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Hemogenyx Secures £2,500,000 to continue its Phase 1 Clinical Trials

 

Introduction

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has
raised £2,500,000 from a consortium of private investors through a direct
subscription for 313,333 new ordinary shares in the Company at a price of
£7.50 per share. The new investors will also receive a three year warrant to
subscribe on a one-for-one basis for ordinary shares in the Company at £9 per
share. Some of these investors taken part in earlier share subscriptions in
recent months and we are grateful for their continuing support.

The net proceeds of this fundraise will be dedicated primarily to the
continuation of the Phase I clinical trials for the Company's Chimeric Antigen
Receptor T-cell therapy ("HG-CT-1"), aimed at treating relapsed/refractory
acute myeloid leukemia ("R/R AML") both in adults and also now in children.

The Company received a positive recommendation from the independent Data
Safety Monitoring Board ("DSMB") overseeing its ongoing Phase I clinical trial
of HG-CT-1 in October 2025, supporting continuation of the trial with
escalation to the next dose level in adults. In addition, the Company has
received clearance from the U.S. Food and Drug Administration ("FDA") to
initiate a Phase I clinical trial in pediatric patients aged 12-18 years.

In parallel, management has undertaken a concerted effort to significantly
reduce the Company's burn rate. As part of this initiative, the Company
outsourced the manufacturing of HG-CT-1 to a specialised external
manufacturer, Made Scientific ("MADE"). The Company devoted substantial time
to the technology transfer process and is currently in the final stages of
this work, in preparation for the manufacture of HG-CT-1 for the first adult
and pediatric patients. The next group of adult patients will be treated with
an increased dose while pediatric patients will receive the lowest dose of
HG-CT-1 which is going to be the same as in the first group of adults.

While the Company's efforts remain primarily focused on the HG-CT-1 clinical
trials, it continues to advance its CDX and CBR product candidates where
possible and expects to report further progress on these programmes in due
course.

An application is being made to the Main Market of the London Stock Exchange,
and admission of the Placing Shares to trading is expected on or around 13
February 2026 ("Admission"). The Placing Shares will rank pari passu with the
Company's existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
6,354,588 ordinary shares. The Company does not hold any shares in treasury.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company, under the
Disclosure

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"We are grateful for the continued support shown by both new and existing
investors in this financing. The proceeds of the fundraise will be used
primarily to support the ongoing Phase I clinical trials of HG-CT-1 in adults
and paediatric patients with relapsed or refractory acute myeloid leukaemia.

Following the positive recommendation from the DSMB to continue the adult
trial at the next dose level and the receipt of FDA clearance to initiate the
paediatric study, the Company remains focused on executing its clinical
programme. In parallel, we have implemented measures to reduce operating
costs, including outsourcing the manufacture of HG-CT-1 to a specialised
third-party provider.

While HG-CT-1 remains our principal priority, we continue to advance our other
programmes where appropriate and will provide updates as and when further
progress is made."

 

UK Market Abuse Regulation (UK MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 AlbR Capital Limited                                            Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City .

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEVKLFBQLLBBBQ



            Copyright 2019 Regulatory News Service, all rights reserved